Sign In
Buy MEDP
Medpace Holdings Earnings Calls
| Release date | Apr 22, 2026 |
| EPS estimate | $3.74 |
| EPS actual | $4.28 |
| EPS Surprise | 14.44% |
| Revenue estimate | 697.598M |
| Revenue actual | 706.604M |
| Revenue Surprise | 1.29% |
| Release date | Feb 09, 2026 |
| EPS estimate | $4.19 |
| EPS actual | $4.67 |
| EPS Surprise | 11.46% |
| Revenue estimate | 689.313M |
| Revenue actual | 708.45M |
| Revenue Surprise | 2.78% |
| Release date | Oct 22, 2025 |
| EPS estimate | $3.53 |
| EPS actual | $3.86 |
| EPS Surprise | 9.35% |
| Revenue estimate | 640.997M |
| Revenue actual | 659.903M |
| Revenue Surprise | 2.95% |
| Release date | Jul 21, 2025 |
| EPS estimate | $2.98 |
| EPS actual | $3.10 |
| EPS Surprise | 4.03% |
| Revenue estimate | 538.774M |
| Revenue actual | 603.311M |
| Revenue Surprise | 11.98% |
Last 4 Quarters for Medpace Holdings
Below you can see how MEDP performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 21, 2025 |
| Price on release | $308.88 |
| EPS estimate | $2.98 |
| EPS actual | $3.10 |
| EPS surprise | 4.03% |
| Date | Price |
|---|---|
| Jul 15, 2025 | $312.71 |
| Jul 16, 2025 | $314.83 |
| Jul 17, 2025 | $319.16 |
| Jul 18, 2025 | $311.87 |
| Jul 21, 2025 | $308.88 |
| Jul 22, 2025 | $477.73 |
| Jul 23, 2025 | $437.41 |
| Jul 24, 2025 | $455.68 |
| Jul 25, 2025 | $447.49 |
| 4 days before | -1.22% |
| 4 days after | 44.88% |
| On release day | 54.67% |
| Change in period | 43.10% |
| Release date | Oct 22, 2025 |
| Price on release | $546.74 |
| EPS estimate | $3.53 |
| EPS actual | $3.86 |
| EPS surprise | 9.35% |
| Date | Price |
|---|---|
| Oct 16, 2025 | $521.21 |
| Oct 17, 2025 | $528.07 |
| Oct 20, 2025 | $544.41 |
| Oct 21, 2025 | $545.64 |
| Oct 22, 2025 | $546.74 |
| Oct 23, 2025 | $596.61 |
| Oct 24, 2025 | $605.20 |
| Oct 27, 2025 | $596.48 |
| Oct 28, 2025 | $580.53 |
| 4 days before | 4.90% |
| 4 days after | 6.18% |
| On release day | 9.12% |
| Change in period | 11.38% |
| Release date | Feb 09, 2026 |
| Price on release | $530.35 |
| EPS estimate | $4.19 |
| EPS actual | $4.67 |
| EPS surprise | 11.46% |
| Date | Price |
|---|---|
| Feb 03, 2026 | $568.53 |
| Feb 04, 2026 | $561.52 |
| Feb 05, 2026 | $541.27 |
| Feb 06, 2026 | $542.04 |
| Feb 09, 2026 | $530.35 |
| Feb 10, 2026 | $446.05 |
| Feb 11, 2026 | $423.93 |
| Feb 12, 2026 | $416.04 |
| Feb 13, 2026 | $428.03 |
| 4 days before | -6.72% |
| 4 days after | -19.29% |
| On release day | -15.90% |
| Change in period | -24.71% |
| Release date | Apr 22, 2026 |
| Price on release | $508.46 |
| EPS estimate | $3.74 |
| EPS actual | $4.28 |
| EPS surprise | 14.44% |
| Date | Price |
|---|---|
| Apr 16, 2026 | $515.65 |
| Apr 17, 2026 | $520.60 |
| Apr 20, 2026 | $528.44 |
| Apr 21, 2026 | $514.90 |
| Apr 22, 2026 | $508.46 |
| Apr 23, 2026 | $393.42 |
| Apr 24, 2026 | $410.54 |
| Apr 27, 2026 | $421.37 |
| Apr 28, 2026 | $409.76 |
| 4 days before | -1.39% |
| 4 days after | -19.41% |
| On release day | -22.63% |
| Change in period | -20.54% |
Medpace Holdings Earnings Call Transcript Summary of Q1 2026
Key points for investors:
- Q1 2026 revenue was $706.6M, up 26.5% year-over-year. EBITDA was $149.4M (21.1% margin) and net income was $123.9M. EPS was $4.28. Results were strong on a reported and constant-currency basis.
- Net new business awards (net bookings) were $618.4M in the quarter, producing a net book-to-bill of 0.88. Ending backlog was ~$2.9B (up 2.9% YoY) with ~$1.94B expected to convert to revenue in the next 12 months; backlog conversion in Q1 was 23.3%.
- Cancellations were elevated (the highest in over a year), pressuring net bookings. Cancellations were concentrated mainly in oncology and cardiovascular; management said these cancellations appeared to be program-specific (product performance, reprioritizations) rather than broad funding-driven pullbacks.
- Management reconfirmed full-year 2026 guidance for revenue, EBITDA, net income and EPS (assumptions: effective tax rate 19–20%, interest income $27.5M). Kevin Brady noted reconfirmation despite the Q1 cancellation headwind.
- Cash/financial position: $652.7M cash on hand; operating cash flow of $151.8M in Q1; negative DSO (–58.8 days). Top 5 and top 10 customers were ~28% and ~37% of LTM revenue, respectively.
- Hiring and investment: Medpace continues to hire and invest (including in AI capabilities). Management expects near-term AI investments to offset productivity gains, with net benefits likely a few years out.
- Management change: This was President Jesse Geiger’s last earnings call after 18.5 years; August Troendle (CEO) will retake day-to-day President duties in the near term.
- Risks/near-term outlook: Elevated cancellations and softer gross awards in the quarter create uncertainty for sequential revenue cadence; management is focused on expanding and improving pipeline and win rate to offset cancellations.
Bottom line: Financials remain healthy with strong revenue and cash generation, but elevated cancellations have reduced book-to-bill and create near-term uncertainty. Management reaffirmed full-year guidance and is prioritizing pipeline expansion and win-rate initiatives while continuing to invest in capabilities (including AI) for longer-term productivity gains.
